|
94 Companies |
|
165 Products |
|
165 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
1453 News |
|
| «12...678910111213141516...2930» |
- rosuvastatin / Generic mfg.
Trial completion: Vascular and Metabolic Effects of Rosuvastatin (clinicaltrials.gov) - Nov 4, 2014
P4, N=160, Completed, Sponsor: Gachon University Gil Medical Center
Recruiting --> Completed
- Clinical: Effects of a Bakery Product Enriched With Fibre and L-carnitine on Insulin Resistance in Patients With Metabolic Syndrome (clinicaltrials.gov) - Nov 3, 2014
P=N/A, N=54, Completed, Sponsor: Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
- ||||| rosuvastatin / Generic mfg.
New P4 trial: Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia (clinicaltrials.gov) - Oct 31, 2014
P4, N=212, Recruiting, Sponsor: Dong-A ST Co., Ltd.
- |||| atorvastatin / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: EASY-FIT: Change in Plaque Characteristics With Atorvastatin (clinicaltrials.gov) - Oct 30, 2014
P4, N=70, Completed, Sponsor: Wakayama Medical University
Recruiting --> Completed Not yet recruiting --> Completed | Initiation date: Jun 2008 --> Aug 2009 | Trial primary completion date: Jun 2010 --> Feb 2012
- ||| Trial completion, Enrollment change: Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=951, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Completed | Initiation date: Jun 2008 --> Aug 2009 | Trial primary completion date: Jun 2010 --> Feb 2012 Active, not recruiting --> Completed | N=2400 --> 951
- ||| Trial completion, Enrollment change: Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=1096, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed | N=2400 --> 951 Active, not recruiting --> Completed | N=1600 --> 1096
- ||| Trial completion, Enrollment change: Diabetic Under 70 (Diabetics Below 70) (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=685, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed | N=1600 --> 1096 Active, not recruiting --> Completed | N=1400 --> 685
- |||| Trial primary completion date: Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels (clinicaltrials.gov) - Oct 28, 2014
P3, N=210, Recruiting, Sponsor: PreEmptive Meds, Pvt. Ltd
Active, not recruiting --> Completed | N=1400 --> 685 Trial primary completion date: Jul 2014 --> Nov 2014
- Fabrazyme (agalsidase beta) / Sanofi, Replagal (agalsidase alfa) / Samaritan Pharma, Takeda
Trial completion: Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. (clinicaltrials.gov) - Oct 28, 2014
P4, N=39, Completed, Sponsor: Rigshospitalet, Denmark
Trial primary completion date: Jul 2014 --> Nov 2014 Active, not recruiting --> Completed
- | Galafold (migalastat) / Amicus
Trial primary completion date: Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease (clinicaltrials.gov) - Oct 22, 2014
P3, N=20, Recruiting, Sponsor: Amicus Therapeutics
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Dec 2015
- Trial withdrawal: A Long-Term Study of Cholesterol Supplements for Smith-Lemli-Opitz Syndrome (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=0, Withdrawn, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Trial primary completion date: Dec 2014 --> Dec 2015 Completed --> Withdrawn
- Trial completion: HCPC: Study of Medical Assistant Health Coaching in Primary Care for Patients With Chronic Conditions (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=441, Completed, Sponsor: University of California, San Francisco
Completed --> Withdrawn Active, not recruiting --> Completed
- Enrollment closed: Outer Thigh Study With Varied Treatment Parameters (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=45, Active, not recruiting, Sponsor: Zeltiq Aesthetics
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Trial completion, Enrollment change, Trial primary completion date: Pilot Study on the Submental Area (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=14, Completed, Sponsor: Zeltiq Aesthetics
Recruiting --> Active, not recruiting Recruiting --> Completed | N=30 --> 14 | Trial primary completion date: Apr 2014 --> Oct 2014
- | Trial completion, Enrollment change, Trial primary completion date: Pilot Study of CoolTXT for Non-Invasive Fat Reduction (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=18, Completed, Sponsor: Zeltiq Aesthetics
Recruiting --> Completed | N=30 --> 14 | Trial primary completion date: Apr 2014 --> Oct 2014 Active, not recruiting --> Completed | N=100 --> 18 | Trial primary completion date: Dec 2012 --> Oct 2014
- |||| Praluent (alirocumab) / Sanofi, Regeneron
Trial primary completion date: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II) (clinicaltrials.gov) - Oct 17, 2014
P3, N=660, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed | N=100 --> 18 | Trial primary completion date: Dec 2012 --> Oct 2014 Trial primary completion date: Sep 2014 --> May 2014
- ||| Enrollment open: Use of Decision Aids in Clinical Encounters (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=400, Enrolling by invitation, Sponsor: Mayo Clinic
Trial primary completion date: Sep 2014 --> May 2014 Active, not recruiting --> Enrolling by invitation
- Fabrazyme (agalsidase beta) / Sanofi, Replagal (agalsidase alfa) / Samaritan Pharma, Takeda
Enrollment closed: Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: O & O Alpan LLC
Active, not recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- |||||||||| fenofibrate nanoparticle formulation / Generic mfg.
New P3 trial, Combination therapy, Monotherapy: Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia (clinicaltrials.gov) - Oct 11, 2014
P3, N=360, Not yet recruiting, Sponsor: IlDong Pharmaceutical Co Ltd
- |||||| Repatha (evolocumab) / Amgen, Astellas
Enrollment open: EBBINGHAUS: Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (clinicaltrials.gov) - Oct 11, 2014
P3, N=4000, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Praluent (alirocumab) / Sanofi, Regeneron
Trial primary completion date: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH) (clinicaltrials.gov) - Oct 11, 2014
P3, N=107, Active, not recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2013 --> May 2014
- ||| Enrollment open: CEPHEUSII: CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II) (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=2700, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Nov 2013 --> May 2014 Not yet recruiting --> Recruiting
- |||| bococizumab (RN316) / Pfizer
Trial primary completion date: SPIRE-HR: Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (clinicaltrials.gov) - Oct 10, 2014
P3, N=600, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2016 --> Apr 2016
- ||||| bococizumab (RN316) / Pfizer
Enrollment change: SPIRE-SI: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins (clinicaltrials.gov) - Oct 10, 2014
P3, N=150, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jan 2016 --> Apr 2016 N=300 --> 150
- ||||| bococizumab (RN316) / Pfizer
Enrollment change, Trial primary completion date: SPIRE-LDL: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events (clinicaltrials.gov) - Oct 10, 2014
P3, N=1932, Recruiting, Sponsor: Pfizer
N=300 --> 150 N=1600 --> 1932 | Trial primary completion date: Dec 2015 --> Jun 2016
- Enrollment change: MK0354 Clinical Efficacy and Tolerability Study (0354-004) (clinicaltrials.gov) - Oct 10, 2014
P2, N=65, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=1600 --> 1932 | Trial primary completion date: Dec 2015 --> Jun 2016 N=252 --> 65
- Clinical: Effect of Different Fat Enriched Meats on the Hepatic Cholesterol Synthesis (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=20, Completed, Sponsor: Instituto Aragones de Ciencias de la Salud
- Biomarker, Enrollment open: Study of the Effects of Blackcurrant Extract and Omega-3 Fats on the Health of the Heart and Blood Vessels (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=102, Recruiting, Sponsor: National Institute of Nursing Research (NINR)
N=252 --> 65 Not yet recruiting --> Recruiting
- rosuvastatin / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels (clinicaltrials.gov) - Oct 10, 2014
P4, N=21, Completed, Sponsor: Juan A. Arnaiz
Not yet recruiting --> Recruiting Not yet recruiting --> Completed | N=60 --> 21 | Trial primary completion date: Mar 2015 --> Sep 2014
- atorvastatin / Generic mfg.
Trial completion: Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients (clinicaltrials.gov) - Oct 10, 2014
P4, N=310, Completed, Sponsor: Poznan University of Medical Sciences
Not yet recruiting --> Completed | N=60 --> 21 | Trial primary completion date: Mar 2015 --> Sep 2014 Recruiting --> Completed
- |||| bococizumab (RN316) / Pfizer
Trial primary completion date: SPIRE-FH: A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Oct 10, 2014
P3, N=300, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Trial primary completion date: Jan 2016 --> May 2016
- |||| Praluent (alirocumab) / Sanofi, Regeneron
Trial primary completion date: ODYSSEY FH I: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (clinicaltrials.gov) - Oct 10, 2014
P3, N=486, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Jan 2016 --> May 2016 Trial primary completion date: Oct 2013 --> Apr 2014
- |||||||||| evacetrapib (LY2484595) / Eli Lilly
New P3 trial: A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia (clinicaltrials.gov) - Oct 10, 2014
P3, N=52, Not yet recruiting, Sponsor: Eli Lilly and Company
- |||||||||| evacetrapib (LY2484595) / Eli Lilly
New P3 trial, Combination therapy: A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia (clinicaltrials.gov) - Oct 10, 2014
P3, N=147, Not yet recruiting, Sponsor: Eli Lilly and Company
- Trial completion: IDOCC: Improved Delivery of Cardiovascular Care Through Outreach Facilitation (clinicaltrials.gov) - Oct 10, 2014
P1, N=194, Completed, Sponsor: C. T. Lamont Primary Care Research Centre
Trial primary completion date: Oct 2013 --> Apr 2014 Recruiting --> Completed
- Enrollment change, Trial primary completion date: RRR: Reducing Risk of Recurrence (clinicaltrials.gov) - Oct 4, 2014
P=N/A, N=150, Recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Completed N=202 --> 150 | Trial primary completion date: Jul 2014 --> Feb 2015
- || Enrollment closed: Use of Decision Aids in Clinical Encounters (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=400, Active, not recruiting, Sponsor: Mayo Clinic
N=202 --> 150 | Trial primary completion date: Jul 2014 --> Feb 2015 Not yet recruiting --> Active, not recruiting
- | Trial completion, Enrollment change, Trial primary completion date: Effect of Beta-Glucan on Cholesterol Lowering (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=45, Completed, Sponsor: University of Manitoba
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=37 --> 45 | Trial primary completion date: Mar 2014 --> Feb 2012
- pegunigalsidase alfa (PRX-102) / Protalix, Chiesi
Trial primary completion date: An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients (clinicaltrials.gov) - Sep 29, 2014
P1/2, N=18, Enrolling by invitation, Sponsor: Protalix
Active, not recruiting --> Completed | N=37 --> 45 | Trial primary completion date: Mar 2014 --> Feb 2012 Trial primary completion date: Jul 2014 --> Jul 2015
- ||||||| Repatha (evolocumab) / Amgen, Astellas
Trial completion, Combination therapy, Metastases: Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk (clinicaltrials.gov) - Sep 28, 2014
P3, N=409, Completed, Sponsor: Amgen
Trial primary completion date: Jul 2014 --> Jul 2015 Active, not recruiting --> Completed
- Adherence: MPATPCDNC: Effect of a Treatment of Lifestyle Changes on the Prevalence of Metabolic Syndrome and Body Weight in Mexican Women (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=180, Completed, Sponsor: Mexican National Institute of Public Health
- | nicotinic acid analog (ARI-3037MO) / Arisaph
New P2 trial: Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia (clinicaltrials.gov) - Sep 28, 2014
P2, N=80, Recruiting, Sponsor: Arisaph Pharmaceuticals Inc
- Trial primary completion date: IMPACT: Prevention Trial to Achieve Cardiovascular Targets (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=400, Recruiting, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Jun 2015
- Enrollment closed, Trial primary completion date, HEOR: Using Nudges to Implement Comparative Effectiveness (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: New York University School of Medicine
Trial primary completion date: Dec 2014 --> Jun 2015 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Feb 2015
- ||||||| Kynamro (mipomersen) / Kastle Therap
Trial completion: An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia (clinicaltrials.gov) - Sep 28, 2014
P3, N=145, Completed, Sponsor: Genzyme, a Sanofi Company
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Feb 2015 Active, not recruiting --> Completed
- ||| Clinical: VASALA: Alpha-linolenic Acid and Blood Pressure (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=72, Recruiting, Sponsor: Maastricht University Medical Center
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion: LIPOKAL: Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients (clinicaltrials.gov) - Sep 19, 2014
P4, N=20, Completed, Sponsor: Juan A. Arnaiz
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| obicetrapib (TA-8995) / NewAmsterdam Pharma
New P1 trial: Study of the Electrocardiographic Effects of TA-8995 (clinicaltrials.gov) - Sep 16, 2014
P1, N=135, Recruiting, Sponsor: Xention Ltd
- ||| Trial completion, Trial primary completion date: Longitudinal Study of Cognition With Niemann-Pick Disease, Type C (clinicaltrials.gov) - Sep 12, 2014
P=N/A, N=70, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Sep 2014
- Enrollment closed: Prioritized Clinical Decision Support (CDS) to Reduce Cardiovascular Risk (clinicaltrials.gov) - Sep 11, 2014
P=N/A, N=60, Active, not recruiting, Sponsor: HealthPartners Institute for Education and Research
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Sep 2014 Recruiting --> Active, not recruiting